P revious studies have indicated that acute gastrointestinal bleeding (GIB) is associated with increased mortality and major thromboembolic events, particularly in selected patients, such as those with acute coronary syndrome (ACS) or stroke mainly treated with antithrombotic drugs. [1] [2] [3] [4] [5] However, in real-world clinical settings, more than half of acute GIB events occur in the absence of antithrombotic drug use. [6] [7] [8] Because patients with acute GIB have potentially hypercoagulable blood, 9 thromboembolic events may occur even in the absence of antithrombotic therapy. However, the associations between acute GIB and risks of thromboembolism and mortality in nonselected populations have never been studied. If acute GIB episodes are associated with increased risks of subsequent thromboembolism and mortality, gastroenterologists and specialists for cerebrocardiovascular disease may have to perform a careful follow-up after GIB episodes.
We therefore conducted a long-term cohort study of patients with acute severe GIB and matched non-GIB diagnosed by endoscopy, and aimed to determine whether acute GIB episodes increase the risk of subsequent thromboembolism and mortality.
Methods

Study Design, Setting, and Participants
We conducted a retrospective cohort study of severe acute GIB and non-GIB patients to estimate the risks of thromboembolism and mortality. All patients were adults who underwent endoscopy at the National Center for Global Health and Medicine, Japan between January 2009 and December 2014. Our hospital is one of the largest emergency hospitals (900 beds) in the Tokyo metropolitan area. Data were collected from the recorded electronic endoscopic database (Solemio Endo; Olympus Medical Systems, Tokyo, Japan), 7, 8 supplemented by review of the electronic medical records (MegaOak online imaging system, NEC, Tokyo, Japan).
This electronic database is a searchable collection of records into which physicians or nurses prospectively input endoscopic or clinical findings, diagnosis, and therapy based on certain forms. 7, 8 This study was approved by the institutional review board.
First, we selected overt GIB patients and non-GIB patients as defined below using the endoscopic database ( Figure 1 ). The search identified 1267 consecutive patients who presented with acute, continuous, or frequent overt GIB ("hematochezia," "red blood pre rectum," "melena," "tarry stool," or "hematemesis") and 2657 patients with no apparent episode of GIB who underwent both upper and lower endoscopy at the same time. Endoscopic and clinical data for each patient were then reviewed by expert gastroenterologists (n ¼ 3924). To define the acute severe GIB cohort, we excluded patients (1) with no overt bleeding within 3 days of endoscopy (n ¼ 211), (2) for whom clinical information could not be accurately collected (n ¼ 89), (3) with less than 1 month of follow-up of the GIB episode (n ¼ 173), or (4) who did not fit the following definition of severe acute GIB (n ¼ 308): ongoing bleeding with transfusion of more than 2 U of packed red blood cells in the emergency room or during hospital stay and/or with signs of shock (decrease in systolic blood pressure to <90 mm Hg, pallor, cold sweats, dizziness, syncope, or loss of consciousness). 10, 11 A cohort of 522 acute severe outpatient-onset GIB patients who underwent endoscopy was selected. To define the non-GIB cohort, we excluded patients (1) with a prior history of acute overt GIB (n ¼ 178), (2) with endoscopically verified ulcers or bleeding lesions (n ¼ 102), (3) clinical information could not be accurately collected (n ¼ 211), or (4) with less than 1 month follow-up of endoscopy (n ¼ 263). After application of the exclusion criteria, 2095 non-GIB patients remained. To minimize confounding effects, non-GIB subjects were randomly selected from among individuals matched for age, sex, year of GIB diagnosis, history of thromboembolism, and use of antithrombotic drugs, with a ratio of 1:2. Ultimately, cohorts of 522 severe acute GIB patients and 1044 non-GIB patients who underwent endoscopy were selected for analysis.
Comorbidity and Medication
We evaluated comorbidity using the Charlson comorbidity index, 12 a validated and commonly used predictive index of mortality in GIB research. 13 Among patients on these drugs before and after the index date (defined as the day of discharge because of acute GIB for the GIB cohort, or day of endoscopy for the matched non-GIB cohort), we categorized patients into 3 groups: (1) no drug, no drug use within 1 month before and after the index date; (2) continue, drug use within 1 month before and after the index date; and (3) discontinue, drug use only within 1 month before the index date. Because specific medications (nonsteroidal anti-inflammatory drugs [NSAIDs], low-dose aspirin [LDA] , and nonaspirin antiplatelet drugs) were occasionally interrupted in continued group or resumed in discontinued group, we defined continued group as patients who used the drug for 50% or more of the observational period, and discontinued group as patients who used the drug for less than 20% of the follow-up period according to their cumulative duration of medication use, as previously reported. 14 
Outcomes and Follow-up
The main outcomes of interest were thromboembolism, and death after the index date (defined as the day of discharge because of acute GIB for the GIB cohort, or day of endoscopy for the matched non-GIB cohort). In Japan, because the prescription period under the health care system is limited to 3 months, GIB and non-GIB patients need to visit at least every 3 months for disease-related prescriptions. Non-GIB patients were outpatient subjects who were under long-term follow-up for metabolic disorder or chronic disease. These patients were also periodically followed up every 3 months for monitoring of symptoms, laboratory testing, and imaging, and also had occasion to undergo endoscopy for cancer screening, even as part of the examination of patients without symptoms of the disease. We defined a thromboembolic event as the presence of ACS, stroke, transient ischemic attack, venous thromboembolism (pulmonary embolism or deep vein thrombosis), or arterial thromboembolism. The diagnosis of thromboembolism was based on typical symptoms with imaging modalities including computed tomography, magnetic resonance imaging, coronary angiography, ventilation-perfusion scan, ultrasonography, or electrocardiography. Date and cause of death were ascertained from death certificates and electronic medical record reviews. Cause of death was additionally determined from laboratory tests, multiple imaging modalities, or autopsy.
Statistics
The main clinical outcomes were thromboembolism and mortality, and exposures were the GIB episode and other clinical factors. In the thromboembolic risk analysis, we followed up patients from the index date to the diagnosis of any thromboembolic event, and censored patients at the time of the last visit, end of follow-up (December 31, 2014), or death. In the survival risk analysis, the endpoint was death and data were censored at the time of the last visit, or the end of follow-up (December 31, 2014). The Kaplan-Meier method was used to estimate cumulative incidences of outcomes, and differences were compared with log-rank test. Unadjusted and adjusted hazard ratios (HRs) and 95% confidence intervals (CIs) for the risk of outcomes were estimated by Cox proportional hazards modeling. In multivariate analysis, we adjusted for matching factors, propensity score for GIB, plus 7 factors (hypertension, diabetes, dyslipidemia, cerebrovascular disease history, ACS history, chronic kidney disease, and liver cirrhosis). To estimate the propensity score for GIB, we used a logistic regression model for GIB including 17 factors that are potentially clinically important variables (body mass index !25 kg/m 2 , hypertension, diabetes mellitus, dyslipidemia, chronic kidney disease, liver cirrhosis, treatment history of malignancy, leukemia, history of peptic ulcer disease, congestive heart failure, dementia, hemiplegia, and use of NSAIDs, LDAs, non-LDA antiplatelets, and anticoagulants). Some of these were shown to differ (P < .10) between GIB and non-GIB. The area under the receiver operating characteristic curve for propensity scores for GIB was 0.78 (95% CI, 0.76-0.81).
Next, using Gray's test 15 in the competing risk analysis, we calculated subdistribution HR with 95% CI, treating death without thromboembolism as a competing risk.
To determine whether GIB is a risk factor for mortality in another nonendoscopy cohort, we selected a comparative cohort comprising the general population in Japan. The expected number of all-cause deaths was determined using age-stratified and sex-specific total mortality rate data for Japan, provided by the Statistics Information Department, Minister's Secretariat, Ministry of Health and Welfare, 2014 in Japan. 16 Standardized mortality ratios were calculated as the ratio of observed deaths to the expected number of patient deaths. The 95% CI of the standardized mortality ratios was estimated assuming a Poisson distribution.
Values of P < .05 were considered significant. All statistical analyses were performed using STATA version 13 software (StataCorp, College Station, TX).
Results
Baseline characteristics of the GIB cohort and non-GIB cohort are shown in Table 1 . Scores for the Charlson Comorbidity Index and CHA2DS2-VASc were higher in the GIB cohort than in the non-GIB cohort. Rates of drug discontinuation were higher in the GIB cohort than in the non-GIB cohort. Blood transfusions were administered to 88% of GIB patients (mean AE standard deviation, 7.0 AE 8.3 U; median, 4.0 U; interquartile range, 4-8 U) during the hospital stay, and 36% of patients presented with shock. Among comorbidities, there was a higher rate of chronic kidney disease in the GIB cohort than in the non-GIB cohort (Supplementary Table 1 ). Endoscopy revealed that 71.5% of all GIB were from upper sources and 28.5% were from lower sources (Supplementary Table 1 ). Peptic ulcer disease was the major cause of upper GIB, whereas colonic diverticular bleeding was the major cause of lower GIB.
Thromboembolism Risk
During a mean follow up of 23.7 months (interquartile range, 10.1-34.0 months), thromboembolic event was identified in 60 of the 522 patients (11.5%) in the GIB cohort and 25 of the 1044 patients (2.4%) in the non-GIB cohort (Table 2 ). Cumulative thromboembolism rates at 5 years were 21.5% in the GIB cohort and 6.0% in the non-GIB cohort (log-rank test, P < .001) (Figure 2A ). Overall incidences of thromboembolism were 5.0 per 1000 person-years in the GIB cohort and 0.9 per 1000 person-years in the non-GIB cohort.
Various risk factors for thromboembolism other than GIB were considered. Log-rank testing revealed that risk factors for thromboembolism other than GIB included age !65 years (P ¼ .231), male sex (P ¼ .088), past history of thromboembolism ( Figure 3A ) (P ¼ .007), body mass index 25 kg/m 2 (P ¼ .139), CHAD2DS2-VASc !2 ( Figure 3B ) (P ¼ .269), comorbidity index !2 ( Figure 3C ) (P < .001), NSAID use (P ¼ .098), LDA use ( Figure 3D ) (P < .001), nonaspirin antiplatelet drug use ( Figure 3E ) (P ¼ .004), and anticoagulant use ( Figure 3F ) (P < .001). Multivariate analysis revealed GIB as an independent risk factor for subsequent allthromboembolic events, cerebrovascular events, cardiovascular events, and other thromboembolic events ( Table 2) . In subgroup analysis for antithrombotic drug user and nonusers, a risk of thromboembolism was evident, irrespective of antithrombotic drug use in univariate analysis (Table 2 ). Multivariate analysis revealed that GIB an independent risk factor for subsequent all-thromboembolic events, cerebrovascular events, and cardiovascular events, but not other thromboembolic events irrespective of antithrombotic drug use (Table 2) . NOTE. Thromboembolic events include acute coronary syndrome (n ¼ 32), stroke (n ¼ 32), transient ischemic attack (n ¼ 2), pulmonary embolism (n ¼ 11), deepvein thrombosis (n ¼ 6), and arterial thrombosis (n ¼ 2). Boldface indicates significant P values (P < .05). GIB, gastrointestinal bleeding; HR, hazard ratio; SHR, subdistributional hazard ratio. We adjusted for matching factors, propensity score for GIB, plus 7 factors (hypertension, diabetes, dyslipidemia, cerebrovascular disease history, acute coronary syndrome history, chronic kidney disease, and liver cirrhosis). Figure 2 . Cumulative probability of thromboembolism and mortality rate using the Kaplan-Meier method and competing risk regression. (A) Cumulative thromboembolism rates (95% CI) in the GIB cohort and non-GIB cohort were 8.8% (6.5%-11.8%) versus 1.2% (0.6%-2.1%) at 1 year, and 21.5% (14.1%-32.1%) versus 6.0% (3.6%-16.1%) at 5 years, respectively (log-rank test, P < .001). (B) Cumulative thromboembolism rates by competing risk regression. (C) The cumulative all-cause mortality rate (95% CI) in the GIB and non-GIB cohorts were 12.9% (10.2%-16.3%) versus 5.6% (4.3%-7.2%) at 1 year, and 22.1% (16.2%-29.8%) versus 11.6% (9.2%-14.6%) at 5 years, respectively (log-rank test, P < .001).
In competing risk analysis, cumulative incidence of thromboembolism was higher in the GIB cohort than that in the non-GIB cohort ( Figure 2B ) (subdistribution HR, 5.0; 95% CI, 3.1-8.0; P < .001). Multivariate analysis also revealed that GIB episodes increased the risk of subsequent all-thromboembolic events, cerebrovascular events, and cardiovascular events ( Table 2) .
Mortality Risk
During a mean follow-up of 24.6 months (interquartile range, 11.2-35.6), 83 patients (15.9%) died in the GIB cohort and 86 patients (8.6%) died in the non-GIB cohort (Table 2) . Cumulative all-cause mortality rates at 5 years were 22.1% in the GIB cohort and 11.6% in the non-GIB cohort (log-rank test, P < .001) ( Figure 2C ). Overall incidences of death were 6.6 per 1000 person-years in the GIB cohort and 3.1 per 1000 person-years in the non-GIB cohort.
Various risk factors for mortality other than GIB were considered. Log-rank testing revealed that risk factors for mortality other than GIB were age !65 years ( Figure 4A ) (P ¼ .004), male sex (P ¼ .707), history of thromboembolism (P ¼ .882), body mass index 25 kg/m 2 ( Figure 4B ) (P < .001), CHAD2DS2-VASc !2 (P ¼ .479), comorbidity index !2 ( Figure 4C ) (P < .001), NSAID use ( Figure 4D ) (P ¼ .004), LDA use ( Figure 4E ) (P ¼ .047), nonaspirin antiplatelet drug use ( Figure 4F ) (P ¼ .082), and anticoagulant use (P ¼ .333). Multivariate analysis revealed GIB as an independent risk factor for all-cause mortality ( Table 2 ). In subgroup analysis for antithrombotic drug user and nonusers, mortality risk was evident, irrespective of antithrombotic drug use in univariate analysis (Table 2) . Multivariate analysis revealed GIB as an independent risk factor for mortality in antithrombotic drug users, but not in nonusers.
Compared with the expected mortality rate based on vital statistics data for Japan, the expected number of allcause deaths in patients with acute GIB was 6.92, yielding an standardized mortality ratios of 12.0 (95% CI, 9.4-14.6).
Discussion
We found that patients with a severe GIB episode were at increased risk of subsequent all-thromboembolic events, cerebrovascular events, cardiovascular events, other thromboembolic events, and all-cause mortality compared with non-GIB. Mortality risk in patients with severe GIB was significantly higher compared with the age-sex adjusted general population in Japan. An increased risk of all-thromboembolism and mortality was evident, irrespective of antithrombotic drug use.
In the ACUITY trial of ACS patients, 2 GIB was significantly associated with 1-year mortality (HR, 4.0), myocardial infarction (HR, 1.7), composite ischemia (HR, 1.9), and 30-day outcomes. In results from the CHARISMA trial, mortality was independently associated with bleeding (GIB was most common) (HR, 2.6), myocardial infarction (HR, 2.9), and stroke (HR, 4.2). 3 In 6853 patients with ischemic stroke, GIB was significantly associated with mortality (odds ratio, 3.3), recurrent stroke (odds ratio, 3.7), and myocardial infarction (odds ratio, 2.8) at discharge. 4 Although previous studies have focused on patients with ACS, cerebrovascular disease, or peripheral artery disease, because these patients usually take antithrombotic drugs, 1-5 the risk ratios for thromboembolism or mortality caused by GIB, in previous studies were similar to our results.
The exact mechanisms by which episodes of GIB increase the risk of subsequent thromboembolism or mortality remains unknown, but we suggest 4 possibilities. First, acute episodes of GIB potentially cause a hypercoagulable state. GIB may result in abnormal platelet activation or coagulation cascade at many different levels. 17 When a blood vessel is injured, a cascade of biochemical reactions begins as a necessary pathway to achieving hemostasis by developing a clot. 17, 18 One study indicated that plasma thrombin-antithrombin III complex concentrations were raised during acute GIB episodes (P < .001), compared with an age-matched reference group. 9 Second, in terms of cardiovascular risk, bleeding may reduce oxygen delivery to the myocardium downstream of coronary stenosis. 19 Third, GIB is a well-known cause of cessation of antithrombotic drug, particularly in patients with ACS or atrial fibrillation. 20, 21 Finally, two observational studies of GIB patients on anticoagulants demonstrated that discontinuing anticoagulant use at discharge increased the risks of thromboembolism within 90 days (HR, [14] [15] [16] [17] [18] [19] [20] and death (HR, 3.3). 20, 21 A major limitation of this study is that patients with severe GIB had more comorbidities at baseline and therefore were more likely to develop thromboembolism or die during follow-up. Although we tried to adjust for matching factors, propensity score for GIB, and 7 comorbidities in the current analysis, the multivariate model did not account for all potential adjusted confounders associated with GIB. To determine whether GIB is an independent predictor of thromboembolism or death, a large prospective cohort study should enroll patients in the GIB and non-GIB cohorts that have the same background, including past medical history, comorbidities, and drugs used.
We also recognize other limitations to this study. First, the number of thromboembolic events was relatively low, which might have resulted in insufficient statistical power in multivariate analysis. Second, information was not collected on other drugs known to affect the risk of GIB, including proton-pump inhibitors, corticosteroids, selective serotonin reuptake inhibitors, and spironolactone. Third, we could not analyze thromboembolic risk between the GIB cohort and the general population, because no data are available on thromboembolic incidence in Japan. We tried to make the baseline characteristics in the non-GIB cohort as close as possible to those in the GIB cohort, but our non-GIB cohort might not be representative of the general population. Despite these limitations, the strengths of this study are that all patients underwent endoscopy at the index date and we could assess whether drugs with known risks were continued or discontinued after the index date.
In conclusion, acute GIB was a significant risk factor for late thromboembolism and death, irrespective of antithrombotic drug use compared with non-GIB evaluated by endoscopy. GIB was also a risk factor for mortality compared with the general population. Prevention of thromboembolism and death seems likely to become increasingly important in the long-term management of acute GIB. NOTE. Endoscopic diagnoses in the non-GIB cohort included reflux esophagitis, esophageal hiatal hernia, atrophic gastritis, colorectal adenoma, colonic diverticulosis, and internal hemorrhoid. Boldface indicates significant P values (P < .05). DM, diabetes mellitus; MGIB, middle GIB. b To diagnose acute MGIB, capsule endoscopy or double-balloon endoscopy was performed when the source of bleeding was not identified by upper endoscopy or colonoscopy whenever possible. All 20 MGIB cases were diagnosed by capsule endoscopy or double-balloon endoscopy, identifying erosion/ulcer (n ¼ 11), multiple angioectasia (n ¼ 7), and bleeding from a diverticulum (n ¼ 2).
